Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene's PD-1 Antibody Accepted for NDA Review in China

publication date: Aug 31, 2018

Beijing's BeiGene reported that the National Medical Products Administration of China (NMPA, formerly known as CFDA or CDA) has accepted the company's new drug application for tislelizumab, a PD-1 antibody, as a treatment for relapsed/refractory classical Hodgkin’s lymphoma. In a pivotal Phase II trial, tislelizumab produced an 87% overall response rate and a 61% complete response rate at a median of eight months follow up. More details....

Stock Symbols: (NSDQ: BGNE; HKEX: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.